Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385–9.

Article  CAS  PubMed  Google Scholar 

Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunol Res. 2019;7:100–12.

Article  CAS  PubMed  Google Scholar 

Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, et al. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. 2021;35:3282–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wermke M, Kraus S, Ehninger A, Bargou RC, Goebeler ME, Middeke JM, et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood. 2021;137:3145–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Bu C, Peng Z, Li G, Zhou Z, Ding W, et al. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia. 2022;36:2596–604.

Article  CAS  PubMed  Google Scholar 

Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, et al. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res. 2013;19:247–57.

Article  CAS  PubMed  Google Scholar 

Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, et al. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia. 2017;31:234–7.

Article  CAS  PubMed  Google Scholar 

Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science. 1992;255:1264–6.

Article  CAS  PubMed  Google Scholar 

Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 1992;356:443–6.

Article  CAS  PubMed  Google Scholar 

Weinzierl AO, Rudolf D, Hillen N, Tenzer S, van Endert P, Schild H, et al. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur J Immunol. 2008;38:1503–10.

Article  CAS  PubMed  Google Scholar 

Shi C, Tian Z, Yan J, Zhang M, Sukhumalchandra P, Chang E, et al. Immunotherapy targeting a leader sequence cathepsin G-derived peptide. Leukemia. 2025;39:888–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood. 1997;89:3503–21.

Article  CAS  PubMed  Google Scholar 

Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, et al. Cathepsin G is expressed by acute lymphoblastic leukemia and is a potential immunotherapeutic target. Front Immunol. 2017;8:1975.

Article  PubMed  Google Scholar 

Fujiwara H, Melenhorst JJ, El Ouriaghli F, Kajigaya S, Grube M, Sconocchia G, et al. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin Cancer Res. 2005;11:4495–503.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gorodkiewicz E, Sienczyk M, Regulska E, Grzywa R, Pietrusewicz E, Lesner A, et al. Surface plasmon resonance imaging biosensor for cathepsin G based on a potent inhibitor: development and applications. Anal Biochem. 2012;423:218–23.

Article  CAS  PubMed  Google Scholar 

Crocker J, Skilbeck N. Granulocyte markers cathepsin G and leukocyte elastase are rarely observed in Reed-Sternberg and Hodgkin’s cells. J Clin Pathol. 1987;40:699–700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gregory AD, Hale P, Perlmutter DH, Houghton AM. Clathrin pit-mediated endocytosis of neutrophil elastase and cathepsin G by cancer cells. J Biol Chem. 2012;287:35341–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, et al. Fucosylation enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes. Clin Cancer Res. 2019;25:2610–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, et al. Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo. Leukemia. 2016;30:1475–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154:180–91.

Article  CAS  PubMed  Google Scholar 

Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18:807–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470–81.

Article  CAS  PubMed  Google Scholar 

Lulla PD, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021;137:2585–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naik S, Vasileiou S, Tzannou I, Kuvalekar M, Watanabe A, Robertson C, et al. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL. Blood. 2022;139:2706–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papadopoulos KP, Suciu-Foca N, Hesdorffer CS, Tugulea S, Maffei A, Harris PE. Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood. 1997;90:4938–46.

Article  CAS  PubMed  Google Scholar 

Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019;25:603–11.

Article  CAS  PubMed  Google Scholar 

Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, et al. Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med. 2018;379:2330–41.